Max Robotics — Global Service Robot Directory + US Certification

About

Dr. J. Daniel is a leading surgical oncologist whose research focuses on refining treatment for human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma. His major contributions center on de-escalation strategies and risk stratification to reduce treatment toxicity while preserving excellent oncologic outcomes. His highly cited 2015 study on risk factors for locoregional relapse after transoral robotic surgery (TORS) challenged traditional indications for adjuvant therapy in the HPV era, fundamentally shaping surgical decision-making. Dr. Daniel’s pivotal MC1273 phase 2 trial demonstrated that dose-de-escalated adjuvant chemoradiation after TORS significantly reduces long-term toxic effects while maintaining swallow function and quality of life—a landmark finding with 19 citations that directly impacts survivorship. His practical recommendations on managing close margins after TORS provide actionable guidance for surgeons, and his most recent work on postoperative ctHPVDNA kinetics (2025) pioneers the use of circulating tumor DNA as a real-time biomarker for disease monitoring. With over 49 citations across his core publications, Dr. Daniel’s research bridges the gap between aggressive treatment and functional preservation, establishing evidence-based pathways that minimize morbidity for this highly curable patient population.